What this comparison tells you
Growth hormone-releasing peptide
GHRP-6
EmergingSome studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation.- Evidence type
- Body changes, not proven benefits
- Approval
- No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026
- Approved products
- None identified in the United States.
- Sports status
- Prohibited
- Sources used
- 11 sources
- Last reviewed
- August 30, 2026
A six-amino-acid research peptide. Small human studies show short-term growth-hormone changes, not proven muscle, fat-loss, or other lasting health benefits.
Ghrelin-receptor agonist · GH secretagogue
Ipamorelin
EmergingSome studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation.- Evidence type
- Health results; use not approved
- Approval
- Still being studied; no FDA-approved product identified
- Approved products
- None identified in the United States.
- Sports status
- Prohibited
- Sources used
- 4 sources
- Last reviewed
- July 23, 2026
A short human study measured growth-hormone release, but it did not prove health benefits. A different phase 2 study did not show benefit on its main or other measured outcomes.
How the evidence compares
These are separate questions, not one score. A peptide can be well understood in one area and uncertain in another.
Both peptide columns stay aligned. Read across each row to compare the same question. On smaller screens, each question shows both records together.
Each question shows both records together.
| Question checked | GHRP-6Emerging | IpamorelinEmerging |
|---|---|---|
| Health benefitsDid people's health improve? | GHRP-6Unclear Small studies measured short-term hormone responses. They did not establish muscle gain, fat loss, recovery, or other lasting health outcomes. | IpamorelinLimited A phase 2 trial did not show significant benefit on its key efficacy endpoint. |
| Body changes in peopleWhat body changes did studies in people measure? | GHRP-6Moderate Small studies in healthy men show a short-term growth-hormone response. One small early study measured how GHRP-6 moved through the body. | IpamorelinModerate Dose-escalation work characterizes short-lived GH release in healthy volunteers. |
| Known risksWhat do we know about risks in people? | GHRP-6Limited FDA lists possible immune reactions from peptide impurities or aggregation, plus possible cortisol and blood-sugar effects. Human studies are too small and brief to show uncommon or long-term harms. | IpamorelinLimited Route-specific data are sparse and FDA identifies serious safety concerns. |
| Exact productDo we know what the product contains and how well it was made? | GHRP-6Limited FDA identity records do not establish finished-product quality or approval. Compounded and online products need separate evidence. | IpamorelinUnclear No approved formulation anchors identity, purity, or equivalence in the consumer market. |
| Approval statusIs there a reviewed product for a specific use? | GHRP-6 No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026 | Ipamorelin Still being studied; no FDA-approved product identified |
Questions to ask before you compare
Use these questions to see whether the records match.
- 01
Did a study in people test a health result, or only a hormone change?
- 02
Did any study measure fat loss or muscle gain?
- 03
Is there an FDA-approved product, and as of what date?
- 04
What do current sports rules say?
What sources were used
The number of sources does not prove strength. Different sources answer different questions. A drug label, a trial, a cell study, and an agency review do not mean the same thing.
GHRP-6
11 sources used
- Regulatory6
- Human pharmacology3
- Anti-doping1
- Reference1
Small human studies show short-term hormone effects. In 17 healthy men, GHRP-6 increased growth hormone for a short time. Another study in 9 healthy men found that blocking a body signal called GHRH greatly reduced the response. An early study in 9 healthy men measured GHRP-6 exposure in the body. These studies measured hormones and exposure, not muscle gain, fat loss, recovery, or long-term health.
These studies do not show that GHRP-6 builds muscle, burns fat, speeds recovery, slows aging, or treats a health condition. The studies were small, short, and mainly in healthy men. One study changed the body's GHRH signal to test how the hormone response works. It was not a treatment study. No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. This is a dated database finding, not a claim about every country or future record.
Ipamorelin
4 sources used
- Anti-doping1
- Human pharmacology1
- Randomized trial1
- Regulatory1
The short hormone-response study was in healthy male volunteers. The phase 2 study was after bowel surgery. A dose-escalation study in healthy male volunteers characterized ipamorelin exposure and a short episode of GH release. In a multicenter, double-blind, placebo-controlled phase 2 trial after bowel surgery, the drug was described as well tolerated in that setting but did not significantly improve the key or secondary efficacy outcomes.
Those studies do not establish popular claims about muscle gain, fat loss, recovery, anti-aging, or sleep. They also do not establish the safety or quality of consumer products, compounded combinations, or different routes.
Fact checks for each peptide
Each result applies only to the statement shown. Open its record to see the version and sources.
GHRP-6
“GHRP-6 is a six-amino-acid peptide.”
FDA's identity record lists GHRP-6 as a hexapeptide, which means six amino acids, and gives its sequence. An identity record does not prove approval, quality, or equivalence between products.
- Evidence used
- Official record or product label
- What this result covers
- The FDA-identified GHRP-6 molecule only. This identity fact does not cover every product sold under the name.
“GHRP-6 can raise growth hormone in short human studies.”
Small studies in healthy men measured short-term increases in growth hormone after GHRP-6. One study found that the response depended in large part on GHRH, another body signal. These are hormone measurements, not proof of treatment benefit.
- Evidence used
- Studies of body changes in people
- What this result covers
- Small, short studies in healthy men; hormone response only, not muscle, fat loss, recovery, or other health outcomes.
“A growth-hormone response proves that GHRP-6 builds muscle or burns fat.”
A hormone response is not the same as a lasting health outcome. The reviewed human studies did not establish muscle gain or fat loss.
- Evidence used
- No reliable studies showing this health result in people
- What this result covers
- Muscle, fat-loss, and other lasting outcomes; the reviewed studies measured hormones or exposure only.
“GHRP-6 is FDA-approved in the United States.”
No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. FDA's substance identity record does not mean approval. This is a dated database finding, not a claim about every country or future record.
- Evidence used
- Official record or product label
- What this result covers
- U.S. human drug records checked on August 30, 2026.
“A compounded GHRP-6 product is FDA-approved.”
FDA says it does not approve compounded drugs. Its current 503A list puts GHRP-6 in Category 3. This means the nomination did not have enough support. FDA also lists safety concerns for 503B compounding. A 2019 warning letter said GHRP-6 did not meet the 503A rules in that case.
- Evidence used
- Official record or product label
- What this result covers
- U.S. FDA records about compounded GHRP-6, checked August 30, 2026. This is not legal advice about one product.
“GHRP-6 is allowed in tested sport.”
The 2026 WADA Prohibited List names GHRP-6 under growth hormone-releasing factors. WADA prohibits it at all times, both in and out of competition.
- Evidence used
- Official record or product label
- What this result covers
- Athletes subject to the 2026 WADA Prohibited List; rules can differ by sport and organization.
Ipamorelin
“Ipamorelin stimulates GH release in people.”
A human dose-escalation study measured an episode of GH release. That is a pharmacodynamic effect.
- Evidence used
- Studies of body changes in people
- What this result covers
- Short-term GH pharmacodynamics in the healthy volunteers and route studied.
“A GH response proves better recovery or body composition.”
A biomarker response is not a clinical outcome, and the identified studies did not establish those benefits.
- Evidence used
- No reliable studies showing this health result in people
- What this result covers
- Recovery and body-composition outcomes not established by GH pharmacology or the postoperative-ileus trial.
“Ipamorelin worked in its phase 2 surgical trial.”
The randomized trial reported no significant difference from placebo on its key and secondary efficacy analyses.
- Evidence used
- Health results from a study with randomly assigned groups
- What this result covers
- The postoperative-ileus population, intervention, and efficacy endpoints in the phase 2 trial.
Products with the same ingredient can differ
Evidence applies to the exact product used in a study. Check the peptide's amino-acid order, ingredients and form, how it enters the body, and where it came from. A shared ingredient name does not prove that another vial has the same benefits or risks.
GHRP-6
6 amino acids · synthetic growth hormone-releasing peptide
FDA's identity record describes the GHRP-6 molecule, not a finished drug product. FDA lists GHRP-6 in compounding safety reviews and in its current 503A category list. Products sold online or made by a compounder need separate proof of identity, quality, and approval.
No FDA product label was found for this molecule in the sources reviewed.
- Research on growth-hormone release and human exposure
Ipamorelin
Synthetic pentapeptide · investigational
Human studies used defined study material and routes. They do not establish the identity, safety, or equivalence of compounded mixtures or consumer-market products.
No FDA product label was found for this molecule in the sources reviewed.
- No FDA-approved indication
Sports rules and safety limits
These statuses do not give personal clearance to compete.
GHRP-6
The 2026 WADA Prohibited List names GHRP-6 under growth hormone-releasing factors. It is prohibited in and out of competition. This page is not personal clearance. Athletes must check the current rules that apply to them.
Reviewed Read the governing record ↗FDA lists GHRP-6 among substances that may present safety risks in compounding. FDA notes possible immune reactions from peptide impurities or aggregation, limited safety information, and possible cortisol or blood-sugar effects. This guide gives no dosing, injection, sourcing, or treatment instructions.
Ipamorelin
Growth-hormone secretagogues and mimetics are prohibited under the current WADA framework.
Reviewed Read the governing record ↗FDA identifies immunogenicity, aggregation, impurity, and characterization concerns. The agency also cites serious adverse events, including death, in intravenous gastric-motility research and says it lacks sufficient information for other promoted injectable routes.
Two short peptides that trigger growth hormone
GHRP-6 is a chain of six amino acids. FDA's identity record lists its sequence as His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It is designed to affect growth-hormone release.
Ipamorelin is a lab-made peptide with five amino acids. It acts on the ghrelin receptor and stimulates growth-hormone release.
Both are graded Emerging. GHRP-6's human studies measured body changes only, such as hormone levels. Ipamorelin also has one clinical trial that tested a health outcome.
FDA status and compounding records
No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. FDA's identity record describes the molecule, not a finished drug product. The claim that GHRP-6 is FDA-approved in the United States is graded Misleading.
FDA says it does not approve compounded drugs. Its current 503A list, which covers substances nominated for pharmacy compounding, puts GHRP-6 in Category 3. This means the nomination did not have enough support. A 2019 FDA warning letter said GHRP-6 did not meet the 503A rules in that case.
No FDA-approved ipamorelin product was identified in its July 23, 2026 review. Its record lists no approved use.
What studies in people measured
The GHRP-6 studies were small and in healthy men. In 17 healthy men, GHRP-6 raised growth hormone for a short time. In 9 healthy men, blocking a body signal called GHRH greatly reduced that response. An early study in 9 healthy men measured how GHRP-6 moved through the body.
The claim that GHRP-6 can raise growth hormone in short human studies is graded Supported with scope. That scope covers the hormone response only.
A study that tested rising doses in healthy male volunteers measured a short burst of growth-hormone release after ipamorelin. The claim that ipamorelin stimulates growth-hormone release in people is graded Supported with scope.
Ipamorelin was also tested in a phase 2 trial after bowel surgery. People were randomly assigned to ipamorelin or a placebo, and neither they nor the researchers knew who got which. The trial found no significant benefit on its main or other measured outcomes. The claim that ipamorelin worked in that trial is graded Misleading.
Does GHRP-6 burn fat?
The reviewed studies do not show that it does. They measured growth hormone and how GHRP-6 moved through the body. They did not measure fat loss, muscle gain, recovery, or long-term health.
The claim that a growth-hormone response proves GHRP-6 builds muscle or burns fat is graded Not established. A hormone response is a body measurement. It is not the same as a lasting health result.
One GHRP-6 study changed the body's GHRH signal on purpose to test how the response works. It was not a treatment study.
For ipamorelin, the reviewed studies also did not establish better recovery or body composition. The claim that a growth-hormone response proves those benefits is graded Not established.
Safety, product, and sports limits
FDA lists GHRP-6 among substances that may present safety risks in compounding. FDA notes possible immune reactions from peptide impurities or clumping (aggregation). It also notes limited safety information and possible effects on cortisol and blood sugar.
FDA identifies several concerns with ipamorelin: possible immune reactions, peptide clumping, impurities, and gaps in how the substance is characterized. FDA also cites serious adverse events, including death, in research that gave it into a vein for stomach movement problems. FDA says it lacks enough information about other injection routes that sellers promote.
The human studies of GHRP-6 are too small and brief to show uncommon or long-term harms. No approved product was identified that would confirm the identity or quality of either peptide sold to consumers. Compounded and online products need separate proof of identity, quality, and approval.
The 2026 WADA Prohibited List names GHRP-6 under growth hormone-releasing factors. It is prohibited at all times, as checked on August 30, 2026. Ipamorelin falls under the growth-hormone secretagogues that the current WADA framework prohibits, as checked on July 23, 2026.
The claim that GHRP-6 is allowed in tested sport is graded Misleading. Rules can differ by sport and organization. This page is not personal clearance. No dose, injection, sourcing, or cycling instructions are given here.
What these records cannot answer
- The reviewed records contain no study that compares GHRP-6 with ipamorelin directly, so no result comparison is made.
- No study in either record establishes fat loss or muscle gain, so no body-composition comparison is made.
- Neither record includes adverse-event rates that can be compared between the two.
- The records give no dosing, injection, cycling, or stacking guidance, and none is given here. No study of the two used together is recorded.
- The reviewed records contain no cost or availability data, so none is reported.
This page does not provide dosing, sourcing, or treatment advice.
Read the sources behind the comparison
GHRP-6
Ipamorelin